Table 2.
Nanoparticles for drug delivery of wound healing drugs or biomolecules for the treatment of diabetic wounds in animal models
| NP Composition | Formulation | Biomolecule | Animal Model | Area (cm2) | Time* (Days) | References |
|---|---|---|---|---|---|---|
| PLGA | In (PVA-borate) hydrogel | Insulin | Rat+diabetes 1 | 0.3 | 16 | 78 |
| In poly(ether)urethane– polydimethylsiloxane/fibrin-based scaffolds | VEGF and bFGF | Mice+diabetes 2 (db/db) | 0.5 | 15 | 80 | |
| — | VEGF | Mice+diabetes 2 (db/db) | 0.5 | 19 | 77 | |
| — | EGF | Rat+diabetes 1 | 2.5 | 21 | 81 | |
| In carbopol 980 | Ferulic acid (FA) | Rat+diabetes 1 | 2.5 cm excision | 14 | 79 | |
| Lipid | — | TNFα | Mice+diabetes 2 (db/db) | 0.5 | 16 | 82 |
| Lecithin | In pluronic gel | Deferoxamine | Rat+diabetes 1 | 4 | 11 | 83 |
| Protamine | In calcium alginate hydrogel/hyaluronan oligosaccharide | — | Rat+diabetes 1 | 3 | 16 | 87 |
| ELP | In fibrin gel | KGF | Mice+diabetes 2 (db/db) | 1 | 14 | 84 |
| In fibrin gel | SDF-1 | Mice+diabetes 2 (db/db) | 1 | 28 | 86 | |
| In fibrin gel | SDF-1 | Mice+diabetes 2 (db/db) | 1 | 28 | 86 | |
| Chitosan | Collagen/alginate | Curcumin | Rat+diabetes 1 | 4 | 15 | 156 |
Diabetes type 1 was inducted with aloxan (rabbits) or streptozocin (mice and rats) (*times for complete wound closure or more than 90% of full thickness wounds).
bFGF, basic fibroblast growth factor; ELP, elastin-like protein; KGF, keratinocyte growth factor; STF-1, stromal cell-derived factor-1; TNFα, tumor necrosis factor alpha.